E
Elliot J. Glotfelty
Researcher at National Institutes of Health
Publications - 20
Citations - 323
Elliot J. Glotfelty is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Neuroprotection & Medicine. The author has an hindex of 8, co-authored 15 publications receiving 164 citations. Previous affiliations of Elliot J. Glotfelty include United States Department of the Army & United States Army Medical Research Institute of Chemical Defense.
Papers
More filters
Journal ArticleDOI
Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease.
Shuchun Chen,Shuchun Chen,Seong-Jin Yu,Yazhou Li,Daniela Lecca,Elliot J. Glotfelty,Hee Kyung Kim,Ho-Il Choi,Barry J. Hoffer,Nigel H. Greig,Dong Seok Kim,Yun Wang +11 more
TL;DR: The data suggest that post-treatment with PT302 provides long-lasting Exendin-4 release and reduces neurodegeneration of nigrostriatal dopaminergic neurons in a 6-hydroxydopamine rat model of PD at a clinically relevant dose.
Journal ArticleDOI
Structural, morphological, and functional correlates of corneal endothelial toxicity following corneal exposure to sulfur mustard vapor
Patrick M. McNutt,Kaylie M. Tuznik,Marian R. Nelson,Angie Adkins,Megan E Lyman,Elliot J. Glotfelty,James P. Hughes,Tracey A. Hamilton +7 more
TL;DR: A model is proposed that explains the relationships among SM dose, the biphasic progression, and the various clinical trajectories of corneal SM injury and that provides a mechanism for temporal variations in MGK onset.
Journal ArticleDOI
Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease.
TL;DR: This mini-review describes the development of GLP-1R agonists and their potential therapeutic value in treating Parkinson’s Disease, and presents preclinical data offering insights into the use of monomeric dual- and tri-agonist incretin-based mimetics for neurodegenerative disorders.
Journal ArticleDOI
Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury
Elliot J. Glotfelty,Thomas E. Delgado,Luis B. Tovar-y-Romo,Yu Luo,Barry J. Hoffer,Lars Olson,Tobias Karlsson,Mark P. Mattson,Brandon K. Harvey,David Tweedie,Yazhou Li,Nigel H. Greig +11 more
TL;DR: A growing body of literature supports the use of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon (Gcg) receptor (R) agonists, along with unimolecular combinations of these therapies, for their potent neurotrophic/neuroprotective activities across a variety of cellular and animal models of chronic neurodegenerative diseases.
Journal ArticleDOI
Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis
Daniele Lecca,Yoo Jin Jung,Michael T. Scerba,I Hwang,Yu Kyung Kim,Sun Kim,Sydney Modrow,David Tweedie,Shih Chang Hsueh,Dong Liu,Weiming Luo,Elliot J. Glotfelty,Yazhou Li,Jia Yi Wang,Yu Luo,Barry J. Hoffer,Dong Seok Kim,Ross A. McDevitt,Nigel H. Greig +18 more
TL;DR: Evaluating the efficacy of 3,6'-dithioPomalidomide in 5xFAD Alzheimer's disease mice to test the hypothesis that neuroinflammation is directly involved in the development of synaptic/neuronal loss and cognitive decline is tested.